Last year, we shared an overview of the proposed Biosecure Act and what it could mean for pharmaceutical and life sciences companies. Since then, a lot has changed.
The Biosecure Act has officially become U.S. law. While many of the requirements will roll out over the next year or two, the direction is clear. Federal agencies and federally funded organizations are being asked to take a much closer look at where their biotech equipment, services, and partners come from.
If you work in pharma, biotech, or life sciences, now is the time to prepare.
A Quick Recap of What Changed
The Biosecure Act was signed into law as part of the FY2026 National Defense Authorization Act. Instead of naming specific foreign companies outright, the law gives federal agencies the authority to identify and designate “biotechnology companies of concern.”
These are companies that:
- Provide biotech equipment or services
- Are owned, controlled, or influenced by a foreign adversary government
- Are deemed to pose a national security risk, including through access to sensitive data
The Office of Management and Budget is expected to publish a formal list of these companies by late 2026. Once that happens, restrictions will begin to take effect.
What the Law Will Require
When implementation begins, federal agencies will be prohibited from:
- Procuring biotech equipment or services from designated companies
- Allowing contractors or grant recipients to use those services while performing federally funded work
That means the responsibility does not stop at direct government suppliers. It extends through the supply chain.
There will be transition periods and limited exceptions, but the long-term expectation is clear. Companies receiving federal funds will need to demonstrate that their vendors, equipment, and partners meet the new requirements.
Why This Matters for Supply Chains and Logistics
For pharmaceutical and life sciences companies, this is not just a legal or procurement issue; it’s an operational one.
Supply chains that rely on global biotech vendors may need to shift. Equipment sourcing, manufacturing partnerships, and even data handling processes could come under scrutiny. Logistics providers will play a critical role in helping companies adapt without disrupting production or distribution.
This is especially important for organizations that:
- Support federally funded research
- Manufacture products for government use
- Work with partners across international biotech ecosystems
What Companies Should Be Doing Now
Even though the formal list has not been published yet, there are practical steps companies can take today.
- Start by reviewing your supplier network. Understand where biotech equipment and services originate and who ultimately controls them.
- Build flexibility into your sourcing strategy. Identifying alternative vendors or regional options now can reduce risk later.
- Loop your logistics and supply chain partners into the conversation early. Transitioning suppliers or equipment takes time, planning, and coordination.
- Finally, keep an eye on federal guidance as definitions and timelines become clearer over the next year.
How Langham Logistics Fits Into What’s Next
Langham Logistics works closely with pharmaceutical and life sciences companies that operate in highly regulated environments. As the Biosecure Act moves from legislation to implementation, supply chain agility and compliance will matter more than ever.
With temperature-controlled facilities, national coverage, and experience supporting complex regulatory requirements, Langham is positioned to help clients navigate change without sacrificing reliability or speed.
If you have questions about how upcoming regulations could affect your distribution or supply chain strategy, our team is here to help you think through what comes next.
